Bovine mastitis market

Bovine Mastitis Market, by Type (Clinical Mastitis and Sub-clinical Mastitis), by Product (Antibiotics, Vaccines, Pain Killers, and Others), by Route of Administration (Intra-mammary and Systemic), by Therapy (Lactating Period, Dry Period (Antibiotics, and Teat Sealants)), by End User (Veterinary Centers, Hospital, Clinics, and Others), and by Region (North America, Europe, Asia Pacific, Middle East, Africa, and Latin America) - Size, Share, Outlook, and Opportunity Analysis, 2024 - 2031

Request Free Sample

Mar 2024
CMI4947
204 Pages
Excel & Pdf
Pharmaceutical

Summary

Bovine mastitis is a medical condition that is common in dairy cows. It refers to the inflammation of mammary gland and udder tissue. The disease can cause harm to the milk-secreting tissues in cows, which is one of the main reasons, it is considered as a dangerous condition. The increased global incidence of bovine mastitis is expected to have a positive impact on the overall market growth over the forecast period. When mastitis is discovered, the first aid is to apply ice cubes to the udder surface. Infected milk from diseased teats should be drained three times a day and disposed properly. To ensure hygienic disposal, a 5% phenol solution can be added to the infected milk.

Global bovine mastitis market is estimated to be valued at USD 1,562.9 Mn in 2024 and is expected to exhibit a CAGR of 5.2% during the forecast period (2024-2031).

Figure 1. Global Bovine Mastitis Market Value (USD Mn), By Region, 2024

Rising incidence of bovine mastitis is expected to drive the market growth over the forecast period.

The increasing incidence of bovine mastitis is expected to drive the market growth over the forecast period For instance, the global incidence of bovine mastitis ranges between 0 and 200 cows, according to the Cornell University College of Veterinary Medicine. Furthermore, the University of Glasgow estimates that bovine mastitis will cost between US$19.7 billion and $ 30 billion in annual healthcare costs, globally. Moreover, rising prevalence of bovine mastitis infections during the dry season, as well as the increased benefits of non-antibiotic intramammary products such as Teat Sealants in preventing new intramammary infections during the dry season, are expected to drive the market growth.

Bovine Mastitis Market Report Coverage

Report Coverage	Details
Base Year:	2023	Market Size in 2024:	US$ 1,562.9 Mn
Historical Data for:	2019 to 2023	Forecast Period:	2024 to 2031
Forecast Period 2024 to 2031 CAGR:	5.2%	2031 Value Projection:	US$ 2,232.6 Mn
Geographies covered:	North America: U.S. and Canada Latin America: Brazil, Argentina, Mexico, and Rest of Latin America Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific Middle East: GCC Countries, Israel, and Rest of Middle East Africa: South Africa, North Africa, and Central Africa
Segments covered:	By Type: Clinical Mastitis, Sub-clinical Mastitis By Product: Antibiotics, Vaccines, Pain Killers, Others By Route of Administration: Intra-mammary, Systemic By Therapy: Lactating Period, Dry Period (Antibiotics, Teat Sealants) By End User: Veterinary Centers, Hospital, Clinics, Others
Companies covered:	Zoetis, Merck & Co., Inc., Boehringer Ingelheim International GmbH, Bayer AG, Elanco, Ceva, West Way Health, Norbrook, DeLaval, ImmuCell Corporation, Advanced Animal Diagnostics, and Nimrod Veterinary Products Ltd.
Growth Drivers:	Increasing incidence of bovine mastitis Increasing product launches Technological advances in the field of drug discovery and development for the treatment of bovine mastitis
Restraints & Challenges:	Increased antibiotic resistance Lack of awareness about the disease

Figure 2. Global Bovine Mastitis Market Share, By Therapy, 2024

Recent Developments

In September 2022, Boehringer Ingelheim, a renowned global player in animal health, announced that the Clinical and Laboratory Standards Institute (CLSI) had endorsed enhanced interpretation criteria for Ubrolexin susceptibility testing. The Federation of Veterinarians of Europe (FVE) promotes the practice of conducting susceptibility testing whenever possible to determine the optimal antimicrobial treatment for a particular illness. The capacity to assess the susceptibility of a mastitis-specific antibiotic combination empowers veterinarians to select the optimal treatment, thereby, aiding in resistance prevention.

Increasing product launches for animal healthcare is expected to boost the market growth during the forecast period.

Cows are more susceptible to mastitis during dry off due to the environmental and physiological changes they go through. Because keratin plug growth changes throughout the dry period, a cow's natural barrier against new intramammary infections, pathogen risk is higher. When dry cows are exposed to high levels of environmental infections, National Mastitis Council's Recommended Mastitis Control Program recommends using a teat sealant. For instance, in February 2020 Merck & Co. Inc. announced the launch of Shut Out, a sterile, antibiotic-free barrier and a novel teat sealant solution. The product is intended to be used prior to dry off, in order to help avoid intramammary infections.

Global Bovine Mastitis Market– Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization declared it as a public health emergency in 2020. According to the Coronavirus Disease (COVID-19) Weekly Epidemiological Update by the World Health Organization, the number of COVID-19 cases reported globally as of August 2, 2021 are approximately 198,234,951 confirmed cases with around 4,227,359 deaths. The coronavirus or COVID-19 outbreak started from Wuhan, China and has spread across continents, affecting various industries globally.

Even during the epidemic, despite lockdown and social distancing procedures, the persistent demand for dairy products has surfaced in favor of the market growth. Moreover, as these products fall under the category of essential services, the market is estimated to grow rapidly during the forecast period.

Global Bovine Mastitis Market: Restraint

The increasing antibiotic resistance and lack of awareness about the bovine mestitis disease are the major factors that are expected to hinder growth of the global bovine mastitis market.

Key Players

Major players operating in the global bovine mastitis market include Zoetis, Merck & Co., Inc., Boehringer Ingelheim International GmbH, Bayer AG, Elanco, Ceva, West Way Health, Norbrook, DeLaval, ImmuCell Corporation, Advanced Animal Diagnostics, and Nimrod Veterinary Products Ltd.

Table of Content

Table of Contents

Segmentation

Detailed Segmentation:

- Frequently Asked Questions -

What is the current market size and compound annual growth rate (CAGR) of the global bovine mastitis market during the forecast period (2024-2031)?

Global bovine mastitis market size is estimated to be valued at USD 1,562.9 Mn in 2024 and is expected to exhibit a CAGR of 5.2% between 2024 and 2031.

What are the major factors driving the market growth?

Increasing incidence of bovine mastitis, increasing product launches, and technological advances in the field of drug discovery and development for the treatment of clinical mastitis are the major factors expected to drive growth of the market.

Which is the leading product segment in the market?

Antibiotics segment is the leading product segment in the market.

What are the key factors hampering growth of the market?

Increased antibiotic resistance and lack of awareness about the disease are the major factors restraining growth of the market.

Which are the major players operating in the market?

Major players operating in the market include Ellodi Pharmaceuticals, EsoCap AG, GlaxoSmithKline plc., Major players operating in the market include Zoetis, Merck & Co., Inc., Boehringer Ingelheim International GmbH, Bayer AG, Elanco, Ceva, West Way Health, Norbrook, DeLaval, ImmuCell Corporation, Advanced Animal Diagnostics, and Nimrod Veterinary Products Ltd.